TheraRadar
Clinical-Stage Companies / Immorna Biotherapeutics

Immorna Biotherapeutics

Pre-Approval PRO BETA
6
Total Trials
0
Phase 3
2
Phase 2
2
Recruiting
36
Score

Pipeline by Phase

Phase 3
Phase 2
2
Phase 1
5

Therapeutic Focus

Infectious Disease Herpes Zoster (HZ) Shingles Respiratory Syncytial Virus (RSV) Infectious Diseases

Clinical Trials (6)

NCT06581575 Phase 2 ACTIVE NOT RECRUITING

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

Started: 10/16/2024

NCT06564194 Phase 1 ACTIVE NOT RECRUITING

A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

Started: 9/25/2024

NCT05727839 Phase 1 COMPLETED

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Started: 2/24/2023

NCT06781125 Phase 1 NOT YET RECRUITING

One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors

Started: 3/18/2026

NCT05743335 Phase 1 COMPLETED

A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine

Started: 3/7/2023

NCT05871541 Phase 1 COMPLETED

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

Started: 5/26/2023

Drug Candidates

JCXH-108 JCXH-105 Shingrix JCXH-211 Injection JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion JCXH-221 Active Control (Shingrix)
Activity Status: Active
Last Trial Started: 3/18/2026
Last Trial Ended: 9/30/2024
Trials (12 months): 1
Completed Trials: 3
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.